Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Replimune Group (NASDAQ:REPL) had its price target hoisted by investment analysts at JPMorgan Chase & Co. from $17.00 to $20.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 64.22% from the company’s current price.

Other analysts also recently issued reports about the stock. Weiss Ratings upgraded shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Cantor Fitzgerald cut Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $17.00 in a research report on Tuesday. Wolfe Research raised Replimune Group to an “outperform” rating in a research note on Tuesday. Finally, Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.86.

Replimune Group Price Performance

Replimune Group stock traded down $0.68 during mid-day trading on Friday, hitting $12.18. The stock had a trading volume of 5,571,197 shares, compared to its average volume of 4,978,161. Replimune Group has a one year low of $1.50 and a one year high of $13.90. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $1.02 billion, a P/E ratio of -3.64 and a beta of 0.88. The firm’s 50 day moving average is $10.08 and its 200 day moving average is $7.51.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, sell-side analysts forecast that Replimune Group will post -2.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

Several institutional investors have recently added to or reduced their stakes in the company. Balyasny Asset Management L.P. increased its stake in Replimune Group by 507.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after buying an additional 2,195,448 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in Replimune Group during the 4th quarter worth $17,568,000. Commodore Capital LP bought a new stake in Replimune Group during the 4th quarter valued at $13,851,000. EcoR1 Capital LLC purchased a new stake in shares of Replimune Group in the 1st quarter worth $7,650,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Replimune Group by 2,333.6% in the 4th quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company’s stock worth $8,993,000 after buying an additional 887,157 shares during the period. Institutional investors own 92.53% of the company’s stock.

Trending Headlines about Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1 regimen. The approval gives Replimune its first marketed product after two prior regulatory rejections and could create a revenue base for the biotechnology company. Reuters FDA approval article
• Positive Sentiment: Investors purchased 25,580 REPL call options, roughly 98% above average daily call volume. The activity may indicate increased bullish speculation or hedging around the FDA decision and the company’s commercial launch, although options volume alone does not establish a sustained investment trend.
• Neutral Sentiment: Coverage emphasized that approval came after earlier rejections tied to clinical-data quality and study-design concerns. Those issues remain important for investors monitoring post-approval requirements, confirmatory trials and the broader commercial rollout. Wall Street Journal FDA approval article
• Negative Sentiment: A securities class action was filed in Massachusetts covering investors who acquired Replimune securities from October 20, 2025, through April 10, 2026. The complaint alleges that the company made misleading statements or failed to disclose concerns about its BLA, including reliance on an early analysis of only 40 patients and deficiencies that could have led to FDA rejection. The allegations have not been proven. Gainey McKenna class action announcement
• Negative Sentiment: Several additional law firms, including Robbins, Pomerantz and Bragar Eagel & Squire, announced investigations or investor solicitations concerning alleged misrepresentations about RP1’s efficacy and viability. The mounting legal attention adds reputational, financial and headline risk. Robbins LLP investor alert

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.